Mirjam de Vries

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2015;33(2):159-165
C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis.
Claushuis TAM; de Vries MK; van der Weijden MAC; Visman IM; Nurmohamed MT; Twisk JWR; Van der Horst-Bruinsma IE; Crusius JBA
Article: CLINICAL RHEUMATOLOGY. 2010;29(12):1433-1438
Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography.
de Vries MK; van Drumpt AS; van Royen BJ; van Denderen JC; Manoliu RA; van der Horst-Bruinsma IE
Article: JOURNAL OF RHEUMATOLOGY. 2010;37(11):2340-2344
pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease.
de Vries M; van der Horst-Bruinsma I; van Hoogstraten I; van Bodegraven A; von Blomberg BME; Ratnawati H; Dijkmans B
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2010;39(1):38-41
The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis.
Dik VK; Peters MJL; Dijkmans PA; Van der Weijden MAC; De Vries MK; Dijkmans BAC; Van der Horst-Bruinsma IE; Nurmohamed MT
Article: ARTHRITIS & RHEUMATOLOGY. 2009;61(11):1484-1490
Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJL; Nurmohamed MT; Dijkmans BAC; Hazenberg BPC; Wolbink GJ
Article: ARTHRITIS & RHEUMATOLOGY. 2009;60(5):1324-1330
Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
van Eijk IC; de Vries MK; Levels JHM; Peters MJL; Huizer EE; Dijkmans BAC; van der Horst-Bruinsma IE; Hazenberg BPC; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
Article: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(4):531-535
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
de Vries MK; van der Horst-Bruinsma IE; Nurmohamed MT; Aarden LA; Stapel SO; Peters MJL; van Denderen JC; Dijkmans BAC; Wolbink GJ
Article: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(9):1252-1254
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BAC; Aarden LA; van der Horst-Bruinsma IE

Alla övriga publikationer

Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2009;68(11):1787-1788
Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
de Vries MK; Brouwer E; van der Horst-Bruinsma IE; Spoorenberg A; van Denderen JC; Jamnitski A; Nurmohamed MT; Dijkmans BAC; Aarden LA; Wolbink GJ
Review: CLINICAL RHEUMATOLOGY. 2009;28(8):883-892
Discovertebral (Andersson) lesions of the spine in ankylosing spondylitis revisited.
Bron JL; de Vries MK; Snieders MN; van der Horst-Bruinsma IE; van Royen BJ
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2008;359(23):2496
Adalimumab in juvenile rheumatoid arthritis.
de Vries MK; van der Horst-Bruinsma IE; Wolbink GJ
Editorial comment: ANNALS OF THE RHEUMATIC DISEASES. 2007;66(1):133-134
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BAC; Aarden LA; van der Horst-Bruinsma IE

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI